Halozyme Therapeutics has announced that its wholly-owned subsidiary, Halozyme Hypercon, has signed a global exclusive collaboration and license agreement with Vertex Pharmaceuticals.

 

The deal gives Vertex access to Halozyme’s Hypercon technology for up to three drug targets.

 

Hypercon is a cutting-edge microparticle technology that hyperconcentrates drugs and biologics, reducing injection volume while enabling convenient, at-home administration.

 

"This collaboration with Vertex underscores the versatility and potential of our Hypercon technology to enable small volume, patient-delivered next‑generation biologics," said Helen Torley, President and CEO of Halozyme. 

 

"Vertex is a proven innovator with deep expertise, and we believe Hypercon can play an important role in supporting improved ease of patient access to targeted biologics that have the potential to advance innovation for patients with serious diseases."

 

Mark Bunnage, Executive Vice President and Chief Scientific Officer of Vertex, added, "We are pleased to add Halozyme's Hypercon drug delivery technology to our toolbox as we pursue transformative therapies for patients with serious diseases. We look forward to exploring the full potential of this technology across our programs of interest."

 

Under the agreement, Vertex will make a $15 million upfront payment to Halozyme, along with potential future milestone payments. Halozyme will also receive royalties on net sales of products developed using Hypercon.